{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:47:48Z","timestamp":1782409668995,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10147-026-03055-6","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:15:13Z","timestamp":1779898513000},"page":"1381-1388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study"],"prefix":"10.1007","volume":"31","author":[{"given":"Taisuke","family":"Tobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-1607","authenticated-orcid":false,"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"12","key":"3055_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","volume":"332","author":"TL Rose","year":"2024","unstructured":"Rose TL, Kim WY (2024) Renal cell carcinoma: a review. JAMA 332(12):1001\u20131010. https:\/\/doi.org\/10.1001\/jama.2024.12848","journal-title":"JAMA"},{"issue":"3","key":"3055_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.eururo.2015.02.001","volume":"68","author":"PM Pierorazio","year":"2015","unstructured":"Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME (2015) Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 68(3):408\u2013415. https:\/\/doi.org\/10.1016\/j.eururo.2015.02.001","journal-title":"Eur Urol"},{"issue":"14","key":"3055_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"14","key":"3055_CR4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Kopyltsov E, M\u00e9ndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"issue":"9","key":"3055_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Ju\u00e1rez VM, Hsieh JJ, Basso U, Shah AY, Su\u00e1rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, \u017bo\u0142nierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"issue":"12","key":"3055_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"issue":"12","key":"3055_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr., Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"key":"3055_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","volume":"37","author":"NA Bosma","year":"2022","unstructured":"Bosma NA, Warkentin MT, Gan CL, Karim S, Heng DYC, Brenner DR, Lee-Ying RM (2022) Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Open Sci 37:14\u201326. https:\/\/doi.org\/10.1016\/j.euros.2021.12.007","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"3055_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/ju.0000000000002252","volume":"207","author":"L Nocera","year":"2022","unstructured":"Nocera L, Karakiewicz PI, Wenzel M, Tian Z, Shariat SF, Saad F, Chun FKH, Briganti A, Kapoor A, Lalani AK (2022) Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. J Urol 207(1):16\u201324. https:\/\/doi.org\/10.1097\/ju.0000000000002252","journal-title":"J Urol"},{"key":"3055_CR10","doi-asserted-by":"publisher","first-page":"102377","DOI":"10.1016\/j.ctrv.2022.102377","volume":"106","author":"P Lombardi","year":"2022","unstructured":"Lombardi P, Filetti M, Falcone R, Di Bidino R, Iacovelli R, Ciccarese C, Bria E, Tortora G, Scambia G, Daniele G (2022) New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Cancer Treat Rev 106:102377. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102377","journal-title":"Cancer Treat Rev"},{"issue":"34","key":"3055_CR11","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/jco.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794\u20135799. https:\/\/doi.org\/10.1200\/jco.2008.21.4809","journal-title":"J Clin Oncol"},{"issue":"7","key":"3055_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621\u2013630. https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N Engl J Med"},{"key":"3055_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-3-319-91442-8_5","volume":"211","author":"C Gr\u00fcllich","year":"2018","unstructured":"Gr\u00fcllich C (2018) Cabozantinib: multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res 211:67\u201375. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_5","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"3055_CR14","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/hep.32023","volume":"74","author":"L Torrens","year":"2021","unstructured":"Torrens L, Montironi C, Puigveh\u00ed M, Mesropian A, Leslie J, Haber PK, Maeda M, Balaseviciute U, Willoughby CE, Abril-Fornaguera J, Piqu\u00e9-Gili M, Torres-Mart\u00edn M, Peix J, Geh D, Ramon-Gil E, Saberi B, Friedman SL, Mann DA, Sia D, Llovet JM (2021) Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology 74(5):2652\u20132669. https:\/\/doi.org\/10.1002\/hep.32023","journal-title":"Hepatology"},{"issue":"2","key":"3055_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/0008-5472.can-20-2426","volume":"82","author":"Y Adachi","year":"2022","unstructured":"Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, Goda S, Kimura T, Kodama K, Matsuki M, Miyano SW, Yokoi A, Kato Y, Funahashi Y (2022) Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res 82(2):292\u2013306. https:\/\/doi.org\/10.1158\/0008-5472.can-20-2426","journal-title":"Cancer Res"},{"issue":"1","key":"3055_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","volume":"17","author":"Y Chen","year":"2024","unstructured":"Chen Y, Dai S, Cheng CS, Chen L (2024) Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J Hematol Oncol 17(1):130. https:\/\/doi.org\/10.1186\/s13045-024-01647-1","journal-title":"J Hematol Oncol"},{"issue":"12","key":"3055_CR17","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.mct-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298\u20132308. https:\/\/doi.org\/10.1158\/1535-7163.mct-11-0264","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"3055_CR18","doi-asserted-by":"publisher","first-page":"7570","DOI":"10.1158\/0008-5472.can-10-1267","volume":"70","author":"EB Rankin","year":"2010","unstructured":"Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ (2010) AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 70(19):7570\u20137579. https:\/\/doi.org\/10.1158\/0008-5472.can-10-1267","journal-title":"Cancer Res"},{"issue":"1","key":"3055_CR19","doi-asserted-by":"publisher","first-page":"43676","DOI":"10.1038\/s41598-025-27578-6","volume":"15","author":"T Kato","year":"2025","unstructured":"Kato T, Nakai Y, Sato M, Takao T, Iwanishi T, Toyoda S, Osaki H, Tsujihata M, Okada K, Kakimoto K, Horitani H, Ono Y, Nishimura K, Takada S, Fujita K, Takayama H, Miyake O, Nakayama M, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Nonomura N (2025) Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study. Sci Rep 15(1):43676. https:\/\/doi.org\/10.1038\/s41598-025-27578-6","journal-title":"Sci Rep"},{"issue":"12","key":"3055_CR20","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10147-024-02633-w","volume":"29","author":"T Hara","year":"2024","unstructured":"Hara T, Suzuki K, Okamura Y, Chiba K, Sato R, Matsushita Y, Tamura K, Ishikawa G, Otsuka A, Miyake H (2024) Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. Int J Clin Oncol 29(12):1931\u20131936. https:\/\/doi.org\/10.1007\/s10147-024-02633-w","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"3055_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00262-025-04019-x","volume":"74","author":"C Porta","year":"2025","unstructured":"Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, \u00dcr\u00fcn Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M (2025) Pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: real-world evidences from the international ARON- 1 study. Cancer Immunol Immunother 74(7):196. https:\/\/doi.org\/10.1007\/s00262-025-04019-x","journal-title":"Cancer Immunol Immunother"},{"key":"3055_CR22","doi-asserted-by":"publisher","first-page":"1605282","DOI":"10.3389\/fonc.2025.1605282","volume":"15","author":"MT Bourlon","year":"2025","unstructured":"Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, \u00dcr\u00fcn Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, P\u00e9rez Calabuig E, Conteduca V, Taha T, Rescigno P, Abu-Sini H, Spinelli GP, Manneh Kopp R, Salfi A, Bhuva D, Valdez-Sandoval P, Mendez-Bribiesca S, Fiala O, Buti S, Marques Monteiro FS, Bamias A, Ghosn M, Massari F, Ansari J, Santoni M (2025) Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study. Front Oncol 15:1605282. https:\/\/doi.org\/10.3389\/fonc.2025.1605282","journal-title":"Front Oncol"},{"key":"3055_CR23","doi-asserted-by":"publisher","unstructured":"Hilser T, Darr C, Niegisch G, Schnabel MJ, Foller S, H\u00e4user L, Zsch\u00e4bitz S, Lewerich J, Ivanyi P, Schlack K, Paffenholz P, Daetwyler E, Nieders\u00fc\u00df-Beke D, Gr\u00fcnwald V (2024) Cabozantinib plus nivolumab in adult patients with advanced or metastatic renal cell carcinoma: a retrospective, non-interventional study in a real-world cohort\/GUARDIANS Project. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16172998","DOI":"10.3390\/cancers16172998"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03055-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03055-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03055-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:19:11Z","timestamp":1782407951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03055-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3055"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03055-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Kobe University Hospital (approval no. B240026) and was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}